Masimo Co. (NASDAQ:MASI) Stake Reduced by Victory Capital Management Inc.

Victory Capital Management Inc. cut its holdings in Masimo Co. (NASDAQ:MASI) by 1.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,816 shares of the medical equipment provider’s stock after selling 153 shares during the quarter. Victory Capital Management Inc.’s holdings in Masimo were worth $1,236,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of MASI. Riverview Trust Co purchased a new position in Masimo in the 1st quarter worth about $25,000. GAMMA Investing LLC increased its stake in Masimo by 75.0% in the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 111 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in Masimo by 851.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 295 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 264 shares in the last quarter. Parallel Advisors LLC increased its stake in Masimo by 48.3% in the 4th quarter. Parallel Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $52,000 after purchasing an additional 145 shares in the last quarter. Finally, Lazard Asset Management LLC increased its stake in Masimo by 5,730.0% in the 1st quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock worth $85,000 after purchasing an additional 573 shares in the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on MASI shares. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research note on Wednesday, August 7th. Piper Sandler lifted their price target on Masimo from $160.00 to $165.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Masimo presently has an average rating of “Moderate Buy” and an average target price of $144.67.

Masimo Trading Down 2.3 %

NASDAQ:MASI opened at $111.73 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.09 and a quick ratio of 1.15. Masimo Co. has a fifty-two week low of $75.22 and a fifty-two week high of $153.93. The stock’s 50-day moving average is $114.82 and its two-hundred day moving average is $125.08. The stock has a market cap of $5.94 billion, a PE ratio of 76.01 and a beta of 0.98.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.09. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The company had revenue of $496.30 million for the quarter, compared to analysts’ expectations of $493.92 million. During the same quarter in the previous year, the business posted $0.62 EPS. The business’s revenue for the quarter was up 9.0% on a year-over-year basis. As a group, equities research analysts forecast that Masimo Co. will post 3.87 earnings per share for the current fiscal year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.